Eli Lilly and Company has 63 disclosed EU lobbying meetings from 2024-09-03 to 2026-06-08: 12 with the European Commission and 51 with Members of the European Parliament. Source: EU Transparency Register no. 04657143399-39, Commission disclosures and MEP declarations. Methodology
Eli Lilly and Company
EU lobbying footprint — who they meet, and on what.
- Register no.
- 04657143399-39 ↗
- Disclosed meetings
- 63 (12 Commission · 51 MEP)
- Period
- 2024-09-03 → 2026-06-08
Declared fields of interest: Budget · Business and industry · Climate action · Competition · Customs · Digital economy and society · Economy, finance and the euro · Education and training · Employment and social affairs · Energy · Environment · External relations
Lobbying profile
as declared 2026-03-13- Category
- Companies & groups
- Legal status
- Corporation
- Declared lobbying cost
- €900,000
- Lobbying FTEs
- 1.9
At a glance
- Health6
- Technology1
- Olivér Várhelyi3
- Laszlo Andrejko2
- Flavio Facioni1
- Chiara Galiffa1
- Laszlo Kristoffy1
Disclosed meetings
Newest first, showing the most recent 60 of 63. EC = European Commission, EP = Member of the European Parliament.
- Biotech Actsource ↗
- 2026-05-28ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiChallenges and priorities for health and life sciencessource ↗
- 2026-05-28ECFlavio Facioni · Cabinet of Commissioner Olivér VárhelyiEU initiatives in the field of the pharmaceutical sectorsource ↗
- 2026-05-07ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičLatest developments in EU-US relationssource ↗
- Pharmasource ↗
- Cardiovascular healthsource ↗
- diagnostics in Alzheimer’s diseasesource ↗
- SANT COMMITTEE ONGOING WORKsource ↗
- Pharmasource ↗
- Alzheimer treatment and diagnosticssource ↗
- Healthsource ↗
- Health policysource ↗
- Saúdesource ↗
- 2025-11-04ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiCompetitiveness of the pharma industrysource ↗
- 2025-10-15ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiPharmaceutical packagesource ↗
- Alzheimers Researchsource ↗
- EU pharmaceutical policysource ↗
- Meeting on brain health policy, early Alzheimer’s diagnosis, and upcoming European Brain Council eventsource ↗
- Tematiche Sanitariesource ↗
- Health policysource ↗
- Pharma Packagesource ↗
- Improving Heart and Metabolic Health Across the EUsource ↗
- 2025-06-27ECMichael McGrath · Cabinet of Commissioner Michael McGrathExchange of views on issues relating to competitiveness and corporate sustainabilitysource ↗
- 2025-06-17ECLaszlo Andrejko · Cabinet of Commissioner Olivér VárhelyiEU health policysource ↗
- New healthcare and pharma initiativessource ↗
- Innovative Alzheimer's treatment in Europesource ↗
- Alzheimer treatmentsource ↗
- 2025-05-06ECMarco La Marca · Cabinet of Commissioner Dubravka ŠuicaDemographic Policysource ↗
- 2025-04-30ECLaszlo Andrejko · Cabinet of Commissioner Olivér VárhelyiEU health policysource ↗
- Supplementary Certificatessource ↗
- Pharmaceutical Industry in the EUsource ↗
- Health policysource ↗
- 2025-02-26ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealthcare, biotech and agri-food policiessource ↗
- 2025-02-04ECRainer Becker · DirectorExchange of views on the Clinical Trials Regulation (CTR), In-Vitro Diagnostic Regulation (IVDR) and their interface. Discussion on the clinical trial environment in Europe and globally.source ↗
- Clinical trials regulationssource ↗
- European healthcaresource ↗
- Introductory meeting with representativesource ↗
- Pharmaceutical strategysource ↗
- Incontro conoscitivo e scambio di vedute sul mandato del Parlamento europeosource ↗
- Priorities for the new mandate on healthsource ↗
- Meetingsource ↗
- Pharma regulationsource ↗
- Diabetes and Obesity caresource ↗
- Obésité & Europe de la Santésource ↗
- EU health policysource ↗
- Discussion on Non-Communicable Diseases: Diabetes, Obesity, Cardiovascular Diseases, and Alzheimer’ssource ↗
- Introductory meeting with Eli Lilly and companysource ↗
- Discussion on Alzheimer diseasesource ↗
- Health policysource ↗
- 2024-10-10ECPeter Van Kemseke · Cabinet of President Ursula von der LeyenEB Summitsource ↗
- Government Affairs - Introductory meetingsource ↗
- Pharma legislationsource ↗
- Intellectual Property and EU Legislationsource ↗
- Life Sciencessource ↗
- Innovation and Health policysource ↗
- Meeting with the pharmaceutical sectorsource ↗
- Public healthsource ↗
- Innovation and competitivenesssource ↗
- Introductory Meetingsource ↗
- Pharmaceuticalsource ↗
Lobbying in these areas
Frequently asked
How many EU lobbying meetings has Eli Lilly and Company disclosed?
Eli Lilly and Company (EU Transparency Register no. 04657143399-39) appears in 63 disclosed meetings with EU officials and MEPs between 2024-09-03 and 2026-06-08: 12 with the European Commission and 51 with Members of the European Parliament.
What does Eli Lilly and Company lobby on?
Eli Lilly and Company's disclosed EU meetings most often concern Health, Technology. Every meeting and its topic is listed with its official source on this page.
Who does Eli Lilly and Company meet in Brussels?
Across its disclosed meetings, Eli Lilly and Company has met Commission officials including Olivér Várhelyi, Laszlo Andrejko, Flavio Facioni, and MEPs including CASTILLO Laurent, NEVADO DEL CAMPO Elena, SOKOL Tomislav. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
- EU Transparency Register profile (no. 04657143399-39) ↗
- European Commission meeting disclosures ↗
- European Parliament — MEP meeting declarations ↗
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.